Therapeutic Indications

Conferences & Courses
Targeting Ocular Disorders Targeting Ocular Disorders
October 6-7, 2014 | Boston, MA
Targeting Ocular Disorders will address targeting of ophthalmic medications and treatments and will provide the latest results in the field, along with novel and emerging targets that hold promise in treating these crippling conditions.

Discovery on Target Discovery on Target
October 8-10, 2014 | Boston, MA
Cambridge Healthtech Institute will host its 12th Annual Discovery on Target event showcasing current and emerging “hot” targets for the pharmaceutical industry, October 8 – 10, 2014 in Boston, MA.

Targeting Epigenetic Readers and Chromatin Remodelers Targeting Epigenetic Readers and Chromatin Remodelers
October 8-9, 2014 | Boston, MA
Cambridge Healthtech Institute' s Targeting Epigenetic Readers and Chromatin Remodelers, October 8-10, 2014 in Boston, covers the development of chemical probes, and clinical-stage inhibitors for therapeutic opportunities with targeting BET Bromodomains a




Life Science Media Library
Understanding EMT: Mechanisms and Metastasis to MET Understanding EMT: Mechanisms and Metastasis to MET
February 20, 2012 |
Epethelial Mesenchymal Transition (EMT) plays a critical role in cancer cells, but understanding of its mechanisms is incomplete. EMT causes cells to develop increased motility, invasiveness, and greater resistance to apoptosis. These changes make the cells more like stem cells, allowing them to self renew. This course provides a framework of the underlying molecular mechanisms while addressing stem cells, and cancer progression, cMET and their activity as anti-metastasis agents, and the Mesenchymal-Epethelial Transition (MET) as an essential process for tumor re-initiation, colonization, and metastasis.
CTCs from Bench to Bed CTCs from Bench to Bed
February 20, 2012 |
This course will focus on validation of CTC research data for clinical practice, correlations between CTCs, diagnosis and responses to therapy.
Targeting Cancer Stem Cells Targeting Cancer Stem Cells
November 3, 2011 |
Cancer stem cells (CSCs) have been identified in several types of cancer, and may play a role in tumorigenic growth, metastasis, and therapeutic resistance. New anticancer therapeutics are being developed that will inhibit tumor growth and reduce tumor-initiating cell frequency, improving clinical cancer therapy. The development of new agents that block key CSC pathways will be described, as well as a novel assay for tracking CSCs in cell populations without the need to isolate them, and a CSC screening strategy for discovering therapeutic antibodies.




Publications, Reports, & Whitepapers